{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:08:07Z","timestamp":1788962887117,"version":"build-2803163510"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ascentage Pharma Group Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40264-026-01678-2","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:54:26Z","timestamp":1784134466000},"page":"1135-1159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Management of Targeted Therapies for Relapsed\/Refractory Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"49","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elcin","family":"Omercikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo D.","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","volume":"35","author":"Q Chen","year":"2017","unstructured":"Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35:166\u201374. https:\/\/doi.org\/10.1200\/JCO.2016.68.2856.","journal-title":"J Clin Oncol"},{"key":"1678_CR2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","volume":"36","author":"C Waweru","year":"2020","unstructured":"Waweru C, Kaur S, Sharma S, Mishra N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36:1481\u201395. https:\/\/doi.org\/10.1080\/03007995.2020.1784120.","journal-title":"Curr Med Res Opin"},{"key":"1678_CR3","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014chronic lymphocytic leukemia (CLL). Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed 20 Mar 2026."},{"key":"1678_CR4","unstructured":"American Cancer Society. Key statistics for chronic lymphocytic leukemia. Available at: https:\/\/www.cancer.org\/cancer\/types\/chronic-lymphocytic-leukemia\/about\/key-statistics.html. Accessed 20 Mar 2026."},{"key":"1678_CR5","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cam4.3855","volume":"10","author":"RK Goyal","year":"2021","unstructured":"Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the Medicare population. Cancer Med. 2021;10:2690\u2013702. https:\/\/doi.org\/10.1002\/cam4.3855.","journal-title":"Cancer Med"},{"key":"1678_CR6","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1002\/cam4.2268","volume":"8","author":"SM Kabadi","year":"2019","unstructured":"Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8:3803\u201310. https:\/\/doi.org\/10.1002\/cam4.2268.","journal-title":"Cancer Med"},{"key":"1678_CR7","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2017007294","volume":"1","author":"C Mansfield","year":"2017","unstructured":"Mansfield C, Masaquel A, Sutphin J, et al. Patients\u2019 priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017;1:2176\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2017007294.","journal-title":"Blood Adv"},{"key":"1678_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020:336\u201345. https:\/\/doi.org\/10.1182\/hematology.2020000118.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1678_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1678_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","volume":"92","author":"M Hallek","year":"2017","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946\u201365. https:\/\/doi.org\/10.1002\/ajh.24826.","journal-title":"Am J Hematol"},{"key":"1678_CR11","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"key":"1678_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","volume":"63","author":"T Cochrane","year":"2022","unstructured":"Cochrane T, Enrico A, Gomez-Almaguer D, et al. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma. 2022;63:304\u201314. https:\/\/doi.org\/10.1080\/10428194.2021.1986217.","journal-title":"Leuk Lymphoma"},{"key":"1678_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(17)30909-9.","journal-title":"Lancet Oncol"},{"key":"1678_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMc1805135","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Mobasher M, Kater AP. Venetoclax-rituximab in chronic lymphocytic leukemia. N Engl J Med. 2018;378:2143\u20134. https:\/\/doi.org\/10.1056\/NEJMc1805135.","journal-title":"N Engl J Med"},{"key":"1678_CR15","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042\u201354. https:\/\/doi.org\/10.1200\/JCO.20.00948.","journal-title":"J Clin Oncol"},{"key":"1678_CR16","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722\u20139. https:\/\/doi.org\/10.1200\/JCO.19.00894.","journal-title":"J Clin Oncol"},{"key":"1678_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1513257.","journal-title":"N Engl J Med"},{"key":"1678_CR18","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","volume":"7","author":"FP Tambaro","year":"2020","unstructured":"Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020;7:e168\u201376. https:\/\/doi.org\/10.1016\/S2352-3026(19)30253-4.","journal-title":"Lancet Haematol"},{"key":"1678_CR19","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"MS Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24:4371\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3761.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"1678_CR20","doi-asserted-by":"publisher","first-page":"I2395","DOI":"10.1182\/blood-2022-162319","volume":"140","author":"L Ysebaert","year":"2022","unstructured":"Ysebaert L, Troussard X, Levy V, et al. Real-world efficacy and safety of venetoclax alone and in combination with rituximab in patients with chronic lymphocytic leukemia: interim results of the Verone study. Blood. 2022;140(Suppl 1):I2395\u20136. https:\/\/doi.org\/10.1182\/blood-2022-162319.","journal-title":"Blood"},{"key":"1678_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/01.HS9.0000845572.12203.da","volume":"6","author":"L Ysebaert","year":"2022","unstructured":"Ysebaert L, Troussard X, Levy V, et al. Real-life efficacy and safety of venetoclax monotherapy in relapsed\/refractory chronic lymphocytic leukemia: interim analysis of multicentric study Verone. HemaSphere. 2022;6:570\u20131. https:\/\/doi.org\/10.1097\/01.HS9.0000845572.12203.da.","journal-title":"HemaSphere."},{"issue":"Suppl 1","key":"1678_CR22","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2021-148696","volume":"138","author":"L Scarfo","year":"2021","unstructured":"Scarfo L, Albi E, Quaglia FM. An observational study on patients with relapsed\/refractory chronic lymphocytic leukemia treated with venetoclax-based regimens outside clinical trials in Italy (GIMEMA CLL1920). Blood. 2021;138(Suppl 1):3746. https:\/\/doi.org\/10.1182\/blood-2021-148696.","journal-title":"Blood"},{"key":"1678_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/hon.3122","volume":"41","author":"L Laurenti","year":"2023","unstructured":"Laurenti L, Scarf\u00f2 L, Frustaci AM, et al. Real-world evidence on venetoclax in chronic lymphocytic leukemia: the Italian experience. Hematol Oncol. 2023;41:621\u201330. https:\/\/doi.org\/10.1002\/hon.3122.","journal-title":"Hematol Oncol"},{"key":"1678_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511\u20137. https:\/\/doi.org\/10.3324\/haematol.2018.193615.","journal-title":"Haematologica"},{"key":"1678_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjh.16271","volume":"188","author":"TA Eyre","year":"2020","unstructured":"Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukemia. Br J Haematol. 2020;188:918\u201323. https:\/\/doi.org\/10.1111\/bjh.16271.","journal-title":"Br J Haematol"},{"key":"1678_CR26","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","volume":"25","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25:4264\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0361.","journal-title":"Clin Cancer Res"},{"key":"1678_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1505","volume":"5","author":"C Samuels","year":"2022","unstructured":"Samuels C, Abbott D, Niemiec S, et al. Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia. Cancer Rep. 2022;5:e1505. https:\/\/doi.org\/10.1002\/cnr2.1505.","journal-title":"Cancer Rep."},{"issue":"Suppl 3","key":"1678_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969508.44280.24","volume":"7","author":"Y Herishanu","year":"2023","unstructured":"Herishanu Y, Goldschmidt N, Itchaki G, et al. Real-world effectiveness of venetoclax-based regimens in patients with chronic lymphocytic leukemia in Israel: update from the multicenter prospective REVEAL study. HemaSphere. 2023;7(Suppl 3):e4428024. https:\/\/doi.org\/10.1097\/01.HS9.0000969508.44280.24.","journal-title":"HemaSphere."},{"key":"1678_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood.2020009578","volume":"138","author":"S Ma","year":"2021","unstructured":"Ma S, Seymour JF, Brander DM, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood. 2021;138:836\u201346. https:\/\/doi.org\/10.1182\/blood.2020009578.","journal-title":"Blood"},{"key":"1678_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403. https:\/\/doi.org\/10.1016\/j.molcel.2004.12.030.","journal-title":"Mol Cell"},{"key":"1678_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4642.","journal-title":"Sci Transl Med"},{"key":"1678_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/cpt.553","volume":"101","author":"AW Roberts","year":"2017","unstructured":"Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther. 2017;101:89\u201398. https:\/\/doi.org\/10.1002\/cpt.553.","journal-title":"Clin Pharmacol Ther"},{"key":"1678_CR33","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2019","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2019;36:1973\u201380. https:\/\/doi.org\/10.1200\/JCO.2017.76.6840.","journal-title":"J Clin Oncol"},{"key":"1678_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3324\/haematol.2020.266486","volume":"107","author":"AR Mato","year":"2022","unstructured":"Mato AR, Sharman JP, Biondo JML, et al. The impact of early discontinuation\/dose modification of venetoclax on outcomes in patients with relapsed\/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. Haematologica. 2022;107:134\u201342. https:\/\/doi.org\/10.3324\/haematol.2020.266486.","journal-title":"Haematologica"},{"key":"1678_CR35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1182\/blood.2019002841","volume":"135","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood. 2020;135:1421\u20137. https:\/\/doi.org\/10.1182\/blood.2019002841.","journal-title":"Blood"},{"key":"1678_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01295-3","author":"TE Lew","year":"2022","unstructured":"Lew TE, Seymour JF. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01295-3.","journal-title":"J Hematol Oncol"},{"key":"1678_CR37","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000120","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2020; 357-62. https:\/\/doi.org\/10.1182\/hematology.2020000120.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1678_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ckj\/sfy026","volume":"11","author":"R Wanchoo","year":"2018","unstructured":"Wanchoo R, Bernabe Ramirez C, Barrientos J, Jhaveri KD. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11:670\u201380. https:\/\/doi.org\/10.1093\/ckj\/sfy026.","journal-title":"Clin Kidney J"},{"key":"1678_CR39","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00277-024-05638-7","volume":"103","author":"I Schwaner","year":"2024","unstructured":"Schwaner I, Kuhn T, Losem C, et al. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Ann Hematol. 2024;103:2013\u201320. https:\/\/doi.org\/10.1007\/s00277-024-05638-7.","journal-title":"Ann Hematol"},{"key":"1678_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","volume":"100","author":"F Bouclet","year":"2021","unstructured":"Bouclet F, Calleja A, Dilhuydy MS, et al. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol. 2021;100:987\u201393. https:\/\/doi.org\/10.1007\/s00277-021-04419-w.","journal-title":"Ann Hematol"},{"key":"1678_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.18738","volume":"202","author":"R Figueroa-Mora","year":"2023","unstructured":"Figueroa-Mora R, Rampotas A, Halperin D, et al. Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real-world multicentre retrospective study. Br J Haematol. 2023;202:48\u201353. https:\/\/doi.org\/10.1111\/bjh.18738.","journal-title":"Br J Haematol"},{"issue":"Suppl 15","key":"1678_CR42","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1200\/JCO.2018.36.15_suppl.7529","volume":"36","author":"C Nabhan","year":"2018","unstructured":"Nabhan C, Klink A, Samp J, et al. Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world. J Clin Oncol. 2018;36(Suppl 15):7529. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7529.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1678_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-134938","volume":"136","author":"JE Seymour","year":"2020","unstructured":"Seymour JE, Gribben JG, Davids MS, et al. Assessment of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the clinical trial and post-marketing settings. Blood. 2020;136(Suppl 1):37\u20138. https:\/\/doi.org\/10.1182\/blood-2020-134938.","journal-title":"Blood"},{"key":"1678_CR44","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.18553\/jmcp.2022.22075","volume":"28","author":"KA Rogers","year":"2022","unstructured":"Rogers KA, Lu X, Emond B, et al. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma: a real-world US retrospective study. J Manag Care Spec Pharm. 2022;28:1033\u201345. https:\/\/doi.org\/10.18553\/jmcp.2022.22075.","journal-title":"J Manag Care Spec Pharm"},{"key":"1678_CR45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1080\/03007995.2021.1929894","volume":"37","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Emond B, Manceur AM, et al. Real-world treatment sequencing and healthcare costs among CLL\/SLL patients treated with venetoclax. Curr Med Res Opin. 2021;37:1409\u201320. https:\/\/doi.org\/10.1080\/03007995.2021.1929894.","journal-title":"Curr Med Res Opin"},{"key":"1678_CR46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(17)30012-8.","journal-title":"Lancet Oncol"},{"key":"1678_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578\u201386. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08143.x.","journal-title":"Br J Haematol"},{"key":"1678_CR48","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5858\/arpa.2017-0278-RS","volume":"143","author":"SM Williams","year":"2019","unstructured":"Williams SM. Tumor lysis syndrome. Arch Pathol Lab Med. 2019;143:386\u201393. https:\/\/doi.org\/10.5858\/arpa.2017-0278-RS.","journal-title":"Arch Pathol Lab Med"},{"key":"1678_CR49","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1182\/bloodadvances.2025015818","volume":"9","author":"A Serafin","year":"2025","unstructured":"Serafin A, Cellini A, Martino EA, et al. Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort. Blood Adv. 2025;9:3576\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2025015818.","journal-title":"Blood Adv"},{"key":"1678_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406207221127550","volume":"13","author":"AM Frustaci","year":"2022","unstructured":"Frustaci AM, Del Poeta G, Visentin A, et al. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia. Ther Adv Hematol. 2022;13:1\u201314. https:\/\/doi.org\/10.1177\/20406207221127550.","journal-title":"Ther Adv Hematol"},{"key":"1678_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2025.102219","volume":"16","author":"EA Martino","year":"2025","unstructured":"Martino EA, Vigna E, De Luca P, et al. Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: findings from a prospective single-center cohort study. J Geriatr Oncol. 2025;16:102219. https:\/\/doi.org\/10.1016\/j.jgo.2025.102219.","journal-title":"J Geriatr Oncol"},{"key":"1678_CR52","doi-asserted-by":"publisher","first-page":"E105","DOI":"10.1002\/ajh.26444","volume":"97","author":"MS Davids","year":"2022","unstructured":"Davids MS, Shadman M, Parikh SA, et al. A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed\/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97:E105\u20139. https:\/\/doi.org\/10.1002\/ajh.26444.","journal-title":"Am J Hematol"},{"key":"1678_CR53","unstructured":"Abbvie Inc. and Genentech USA Inc. Venclexta\u00ae (venetoclax) prescribing information. 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf. Accessed 21 Mar 2026."},{"key":"1678_CR54","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O'Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(16)30212-1.","journal-title":"Lancet Oncol"},{"key":"1678_CR55","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2856.","journal-title":"Clin Cancer Res"},{"key":"1678_CR56","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352. https:\/\/doi.org\/10.1200\/JCO.21.01210.","journal-title":"J Clin Oncol"},{"key":"1678_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. HemaSphere. 2022;6:e801. https:\/\/doi.org\/10.1097\/HS9.0000000000000801.","journal-title":"HemaSphere"},{"key":"1678_CR58","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood.2018884940","volume":"135","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135:1204\u201313. https:\/\/doi.org\/10.1182\/blood.2018884940.","journal-title":"Blood"},{"key":"1678_CR59","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035\u201345. https:\/\/doi.org\/10.1200\/JCO.22.00510.","journal-title":"J Clin Oncol"},{"key":"1678_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"key":"1678_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS ONE. 2019;14:e0211228. https:\/\/doi.org\/10.1371\/journal.pone.0211228.","journal-title":"PLoS ONE"},{"key":"1678_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100150","volume":"2","author":"J-W Rhee","year":"2025","unstructured":"Rhee J-W, Lamanna N, Aldairy W, et al. Hypertension in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma in ALPINE: a secondary analysis. Blood Neoplasia. 2025;2:100150. https:\/\/doi.org\/10.1016\/j.bneo.2025.100150.","journal-title":"Blood Neoplasia"},{"key":"1678_CR63","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919\u201328. https:\/\/doi.org\/10.1182\/blood.2019000840.","journal-title":"Blood"},{"key":"1678_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01302-7","volume":"15","author":"ST Chen","year":"2022","unstructured":"Chen ST, Azali L, Rosen L, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol. 2022;15:92. https:\/\/doi.org\/10.1186\/s13045-022-01302-7.","journal-title":"J Hematol Oncol"},{"key":"1678_CR65","doi-asserted-by":"publisher","unstructured":"Quartermaine C, Ghazi SM, Yasin A, et al. Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2023;5:570\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002.","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"1678_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942.","journal-title":"Front Cell Dev Biol"},{"key":"1678_CR67","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363. https:\/\/doi.org\/10.1002\/ajh.25638.","journal-title":"Am J Hematol"},{"key":"1678_CR68","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2022007938.","journal-title":"Blood Adv"},{"key":"1678_CR69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.17788","volume":"196","author":"CPS Tang","year":"2022","unstructured":"Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 2022;196:70\u20138. https:\/\/doi.org\/10.1111\/bjh.17788.","journal-title":"Br J Haematol"},{"key":"1678_CR70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","volume":"3","author":"H Essa","year":"2021","unstructured":"Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to manage atrial fibrillation secondary to ibrutinib. JACC CardioOncol. 2021;3:140\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2020.11.016.","journal-title":"JACC CardioOncol"},{"issue":"Suppl 1","key":"1678_CR71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137062","volume":"136","author":"T Hilal","year":"2020","unstructured":"Hilal T, Hillegass WB, Gonzalez-Velez M, Leis JF, Rosenthal AC. Adverse events in clinical trials of ibrutinib and acalabrutinib for B-cell lymphoproliferative disorders: a systematic review and network meta-analysis. Blood. 2020;136(Suppl 1):23. https:\/\/doi.org\/10.1182\/blood-2020-137062.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1678_CR72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2020-134797","volume":"136","author":"JR Brown","year":"2020","unstructured":"Brown JR, Byrd JC, Ghia P, et al. Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL). Blood. 2020;136(Suppl 1):52\u20134. https:\/\/doi.org\/10.1182\/blood-2020-134797.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1678_CR73","doi-asserted-by":"publisher","first-page":"17859","DOI":"10.1161\/circ.148.suppl_1.17859","volume":"148","author":"MC Polliner","year":"2023","unstructured":"Polliner MC, Buck B, Ghazi S, et al. Real world cardiovascular events with next generation Bruton\u2019s tyrosine kinase inhibitors: an updated analysis. Circulation. 2023;148(Suppl 1):17859. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.17859.","journal-title":"Circulation"},{"key":"1678_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687\u201399. https:\/\/doi.org\/10.1182\/blood.2022018818.","journal-title":"Blood"},{"key":"1678_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049. https:\/\/doi.org\/10.1136\/openhrt-2019-001049.","journal-title":"Open Heart"},{"key":"1678_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061228","volume":"16","author":"FR Mauro","year":"2024","unstructured":"Mauro FR, Scalzulli PR, Scarfo L, et al. Real-world outcome of treatment with single-agent ibrutinib in Italian patients with chronic lymphocytic leukemia: final results of the EVIdeNCE study. Cancers. 2024;16:1228. https:\/\/doi.org\/10.3390\/cancers16061228.","journal-title":"Cancers"},{"key":"1678_CR77","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796\u2013805. https:\/\/doi.org\/10.3324\/haematol.2017.171041.","journal-title":"Haematologica"},{"key":"1678_CR78","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","volume":"107","author":"JR Brown","year":"2022","unstructured":"Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335\u201346. https:\/\/doi.org\/10.3324\/haematol.2021.278901.","journal-title":"Haematologica"},{"key":"1678_CR79","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","volume":"7","author":"S Opat","year":"2023","unstructured":"Opat S, Tedeschi A, Hu B, et al. Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 2023;7:6801\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2023010668.","journal-title":"Blood Adv"},{"key":"1678_CR80","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4:1491\u2013500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004.","journal-title":"JACC Clin Electrophysiol"},{"key":"1678_CR81","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Levy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. an international retrospective study. Br J Haematol. 2016;175:462\u20136. https:\/\/doi.org\/10.1111\/bjh.14324.","journal-title":"Br J Haematol"},{"key":"1678_CR82","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:648\u201357. https:\/\/doi.org\/10.1016\/j.clml.2018.06.016.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1678_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.580622","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Zhao A, Zhou H, et al. Risk of bleeding associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11:580622. https:\/\/doi.org\/10.3389\/fphar.2020.580622.","journal-title":"Front Pharmacol"},{"key":"1678_CR84","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100:1571\u20138. https:\/\/doi.org\/10.3324\/haematol.2015.126672.","journal-title":"Haematologica"},{"key":"1678_CR85","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","volume":"128","author":"MR Fleming","year":"2021","unstructured":"Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ. Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors. Circ Res. 2021;128:1973\u201387. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318259.","journal-title":"Circ Res"},{"key":"1678_CR86","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/10428194.2020.1772477","volume":"61","author":"C Pleyer","year":"2020","unstructured":"Pleyer C, Sun C, Desai S, et al. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leuk Lymphoma. 2020;61:2375\u201382. https:\/\/doi.org\/10.1080\/10428194.2020.1772477.","journal-title":"Leuk Lymphoma"},{"key":"1678_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.105","volume":"6","author":"C da Cunha-Bang","year":"2016","unstructured":"da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6:e499. https:\/\/doi.org\/10.1038\/bcj.2016.105.","journal-title":"Blood Cancer J"},{"key":"1678_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/10428199409056283","volume":"13","author":"S Molica","year":"1994","unstructured":"Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma. 1994;13:203\u201314. https:\/\/doi.org\/10.3109\/10428199409056283.","journal-title":"Leuk Lymphoma"},{"key":"1678_CR89","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178:394\u2013402. https:\/\/doi.org\/10.1111\/bjh.14785.","journal-title":"Br J Haematol"},{"key":"1678_CR90","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100:325\u201334. https:\/\/doi.org\/10.1111\/ejh.13020.","journal-title":"Eur J Haematol"},{"key":"1678_CR91","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955\u20139. https:\/\/doi.org\/10.1182\/blood-2017-11-818286.","journal-title":"Blood"},{"key":"1678_CR92","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"T Varughese","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67:687\u201392. https:\/\/doi.org\/10.1093\/cid\/ciy175.","journal-title":"Clin Infect Dis"},{"key":"1678_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae115","volume":"11","author":"NIA Higuita","year":"2024","unstructured":"Higuita NIA, Chastain DB, Scott B, et al. Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a case-control propensity score-matched analysis. Open Forum Infect Dis. 2024;11:ofae115. https:\/\/doi.org\/10.1093\/ofid\/ofae115.","journal-title":"Open Forum Infect Dis"},{"key":"1678_CR94","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298\u2013307. https:\/\/doi.org\/10.1182\/blood-2018-11-846808.","journal-title":"Blood"},{"key":"1678_CR95","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real world analysis. Haematologica. 2018;103:874\u20139. https:\/\/doi.org\/10.3324\/haematol.2017.182907.","journal-title":"Haematologica"},{"key":"1678_CR96","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","volume":"4","author":"CE Ryan","year":"2020","unstructured":"Ryan CE, Cheng MP, Issa NC, Brown JR, Davids MS. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020;4:1458\u201363. https:\/\/doi.org\/10.1182\/bloodadvances.2020001678.","journal-title":"Blood Adv"},{"key":"1678_CR97","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3390\/cancers15071989","volume":"15","author":"B Pilmis","year":"2023","unstructured":"Pilmis B, Kherabi Y, Huriez P. Infectious complications of targeted therapies for solid cancers or leukemias\/lymphomas. Cancers. 2023;15:1989. https:\/\/doi.org\/10.3390\/cancers15071989.","journal-title":"Cancers"},{"key":"1678_CR98","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","volume":"106","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021;106:2364\u201373. https:\/\/doi.org\/10.3324\/haematol.2020.272500.","journal-title":"Haematologica"},{"key":"1678_CR99","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","volume":"10","author":"M Shadman","year":"2023","unstructured":"Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10:e35-45. https:\/\/doi.org\/10.1016\/S2352-3026(22)00320-9.","journal-title":"Lancet Haematol."},{"key":"1678_CR100","unstructured":"Pharmacyclics LLC and Janssen Biotech Inc. Imbruvica\u00ae (ibrutinib) prescribing information. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/217003s000lbl.pdf. Accessed 21 Mar 2026."},{"key":"1678_CR101","unstructured":"AstraZeneca Pharmaceuticals LP. Calquence\u00ae (acalabrutinib) prescribing information. 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf. Accessed 21 Mar 2026."},{"key":"1678_CR102","unstructured":"BeiGene USA Inc. Brukinsa\u00ae (zanubrutinib) prescribing information. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213217s000lbl.pdf. Accessed 21 Mar 2026."},{"key":"1678_CR103","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","volume":"29","author":"S Ailawadhi","year":"2023","unstructured":"Ailawadhi S, Chen Z, Huang B, et al. Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial. Clin Cancer Res. 2023;29:2385\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3321.","journal-title":"Clin Cancer Res"},{"key":"1678_CR104","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/10428194.2022.2047963","volume":"63","author":"M Cozad","year":"2022","unstructured":"Cozad M, Stump SF, Buhlinger K, et al. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome. Leuk Lymphoma. 2022;63:1831\u20138. https:\/\/doi.org\/10.1080\/10428194.2022.2047963.","journal-title":"Leuk Lymphoma"},{"key":"1678_CR105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13543784.2024.2309873","volume":"33","author":"A Bruzzese","year":"2024","unstructured":"Bruzzese A, Martino EA, Labanca C, et al. Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies. Expert Opin Investig Drugs. 2024;33:73\u20137. https:\/\/doi.org\/10.1080\/13543784.2024.2309873.","journal-title":"Expert Opin Investig Drugs"},{"key":"1678_CR106","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397:892\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)00224-5.","journal-title":"Lancet"},{"key":"1678_CR107","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.2024024510","volume":"144","author":"LE Roeker","year":"2024","unstructured":"Roeker LE, Woyach JA, Cheah CY, et al. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial. Blood. 2024;144:1374\u201386. https:\/\/doi.org\/10.1182\/blood.2024024510.","journal-title":"Blood"},{"key":"1678_CR108","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3324\/haematol.2024.285754","volume":"110","author":"NN Shah","year":"2025","unstructured":"Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial. Haematologica. 2025;110:92\u2013102. https:\/\/doi.org\/10.3324\/haematol.2024.285754.","journal-title":"Haematologica"},{"key":"1678_CR109","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/cancers17030557","volume":"17","author":"RT Salvaris","year":"2025","unstructured":"Salvaris RT, Brennan J, Lewis KL. BTK is the target that keeps on giving: a review of BTK-degrader drug development, clinical data, and future directions in CLL. Cancers (Basel). 2025;17:557. https:\/\/doi.org\/10.3390\/cancers17030557.","journal-title":"Cancers (Basel)"},{"key":"1678_CR110","doi-asserted-by":"publisher","unstructured":"Seymour JF, Parrondo RD, Thompson MC, et al. Updated efficacy\/safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in relapsed\/refractory (R\/R) CLL\/SLL: results from the ongoing phase 1 CaDAnCe-101 study. Hematol Oncol. 2025; 43: e144_70093. https:\/\/doi.org\/10.1002\/hon.70093_144.","DOI":"10.1002\/hon.70093_144"},{"issue":"Suppl 1","key":"1678_CR111","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2024-199116","volume":"144","author":"MC Thompson","year":"2024","unstructured":"Thompson MC, Parrondo RD, Frustaci AM, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study. Blood. 2024;144(Suppl 1):885. https:\/\/doi.org\/10.1182\/blood-2024-199116.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1678_CR112","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2023-179872","volume":"142","author":"A Danilov","year":"2023","unstructured":"Danilov A, Tees MT, Patel K, et al. A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton\u2019s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed\/refractory B cell malignancies. Blood. 2023;142(Suppl 1):4463. https:\/\/doi.org\/10.1182\/blood-2023-179872.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1678_CR113","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2024-194839","volume":"144","author":"NN Shah","year":"2024","unstructured":"Shah NN, Omer Z, Collins GP, et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study. Blood. 2024;144(Suppl 1):884. https:\/\/doi.org\/10.1182\/blood-2024-194839.","journal-title":"Blood"},{"key":"1678_CR114","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.045","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, Pelosi E, Castelli G, Fresa A, Laurenti L. CAR-T cells in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2024;16:e2024045. https:\/\/doi.org\/10.4084\/MJHID.2024.045.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1678_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12:6124. https:\/\/doi.org\/10.3390\/jcm12196124.","journal-title":"J Clin Med"},{"key":"1678_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490. https:\/\/doi.org\/10.3389\/fonc.2024.1396490.","journal-title":"Front Oncol"},{"key":"1678_CR117","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402:641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8.","journal-title":"Lancet"},{"key":"1678_CR118","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175:1298\u2013304. https:\/\/doi.org\/10.7326\/M22-1460.","journal-title":"Ann Intern Med"},{"key":"1678_CR119","unstructured":"International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 2023. Available at: https:\/\/icmje.org\/icmje-recommendations.pdf. Accessed 5 June 2023."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01678-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:12:13Z","timestamp":1788959533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01678-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01678-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The editorial comment has been removed under the heading \u20184.1 BCL-2 Inhibitors\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Ailawadhi, Chanan-Khan, and Paulus serve on the advisory board for Ascentage Pharma. Dr. Paulus also reports that he is the recipient of grants (funding for research purposes) from Ascentage Pharma. Dr. Ailawadhi reports grants and other support from GlaxoSmithKline, Sanofi, Bristol Myers Squibb, Janssen, and Cellectar; other support from Takeda, BeOne, Regeneron, and Pfizer; and grants from Amgen, Pharmacyclics, and AbbVie. Dr. Parrondo reports serving as an investigator for Ascentage Pharma, as well as a consulting or advisory role with Sanofi Aventis GmbH and AstraZeneca, research funding from GlaxoSmithKline and the Bristol Myers Squibb Foundation, as well as providing expert testimony for MJH Life Sciences. Dr. Chanan-Khan reports grant and other support from BeOne, Ascentage Pharma, and AbbVie as well as consultation\/board membership roles in Cellectar and Starton. Dr. Omercikoglu has no financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this review are included in this published article.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were responsible for the conception, planning, and writing of this review. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}